Centrexion secures funding to begin trial of knee osteoarthritis pain drug

This article was originally published here

Centrexion Therapeutics has secured $67m funding to launch phase 3 progam of CNTX-4975 therapy for the treatment of chronic pain due to knee osteoarthritis (OA).

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply